Progyny

PGNY

Market cap $1.52B

Progyny (PGNY) is undervalued at 9.3x forward P/E, with strong cash flow, expanding margins, and a resilient business model post-Amazon client loss. Headline FY26 growth appears muted (5.1%–9%) due to tough comps, but underlying growth excluding Amazon is 9.3–13.3%, with stable utilization rates near 1% and covered lives still expanding. PGNY's differentiated, outcome-focused platform, high retention, and buybacks (~15% share reduction in two years) support a robust medium-term investment case.

Progyny, Inc. (PGNY) Q4 2025 Earnings Call Transcript

Progyny (PGNY) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.42 per share a year ago.

The headline numbers for Progyny (PGNY) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Reports Revenue of $318.4 Million, Reflecting Fourth Quarter Growth of 6.7% and 10% for the Full YearGenerated Record $210.2 Million in Full Year Operating Cash FlowReturned Value to Shareholders Through Repurchase of Approximately 6.5 Million Shares To Date Under Recent AuthorizationIssues Financial Guidance for 2026, Reflecting Tenth Consecutive Year of Revenue Growth

Besides Wall Street's top-and-bottom-line estimates for Progyny (PGNY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.

NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period and full year ended December 31, 2025, after the close of the market on Thursday, February 26, 2026.

Progyny, Inc. (PGNY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women's health and family building solutions, today announced that the Company is participating in the 44th Annual JP Morgan Healthcare Conference, where it intends to discuss its updated expectations for the quarter and year ending December 31, 2025. “As the fourth quarter progressed, we were pleased to see that member engagement has paced favorably as compared to the guidance we issued in November,” said Pete Anevski, Progyny's Chief Executive Officer.

Progyny (PGNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.